DOP069 Improved quality of care and quality of life for IBD patients using mobile based remote monitoring platform: A randomised control trial

Patients with IBD are ideal candidates for mobile-based remote monitoring care that is centred on enhanced symptom tracking and improved communication with care teams. The objective of this pragmatic randomised controlled trial is to determine the impact of the HealthPROMISE app in improving outcomes quality of care [QOC] and quality of life [QOL] as compared with a patient education app. Participants were randomised into intervention (HealthPROMISE) or control group. Primary analysis was a comparison of the change in QOC between both groups. Secondary analyses were made between the two groups for disparities in IBD-related emergency room visits and hospitalisations, change in QOL score from baseline, and proportion of patients reporting controlled disease status. HealthPROMISE patients update their information and receive a disease summary of QOC metrics and IBD-specific QOL trends (Figure 1). Detailed workflow for the HealthPROMISE study. Ongoing collection of follow-up exit survey data captures overall medication adherence, system usability scale, SIBDQ, patient activation measures, and general health status. Out of 320 patients enrolled, 162 were randomised to intervention group and 158 to control group (Females 49.1%; White 82.2%; Black 5.3%; Hispanics 9.1%; English as primary language 96.3%; Everyday Computer Usage 93.4%). IBD-QOL continued to improve among HealthPROMISE patients over a follow-up of 575 days (25.2 ± 11.3 vs. 30.3 ± 11.3 baseline, p < 0.001). Patients reported that uncontrolled anxiety (89.4%) and uncontrolled fatigue (80.9%) were major drivers of poor QOL. After an average follow-up of 495 ± 135 days, QOC improved among all patients (78% vs. 59% control), with a more significant increase observed among HealthPROMISE users (+28 ppt vs. +9 ppt, p < 0.01). After a second follow-up of 575 ± 135 days, compared with control, HealthPROMISE patients experienced a significantly greater increase in QOC from baseline (+34 ppt vs. +15 ppt, p < 0.01) (Figure 2). Change in percentage of patients meeting eligible QOC metrics at 495 days from baseline (+9 pp control vs. +28 pp HealthPROMISE, p < 0.01) and at 575 days from baseline (+15 ppt control vs. +34 ppt HealthPROMISE, p < 0.01). A significant improvement in QOC was observed among patients using HealthPROMISE. IBD patients engaging with HealthPROMISE reported more equitable participation in their care decision-making process, and showed improved health outcomes. Digital health interventions and IBD remote monitoring can address gaps in QOC, increase patient engagement, and improve health outcomes.